FORT LAUDERDALE, Florida, August 5, 2026: The Rumbaugh Goodwin Institute for Cancer Research at Nova Southeastern University (NSU) has filed a patent application with the United States Patent and Trademark Office (USPTO) to protect the intellectual property (IP) associated with the discovery and therapeutic use of the dual DNA/histone methyltransferase inhibitor, CM-272 (also known as RD3), for the treatment of high-risk neuroblastoma. The preliminary data supporting the patent claims were generated through funding provided by a grant from the National Pediatric Cancer Foundation (NPCF), together with financial support from the Royal Dames of Cancer Research Inc. of Fort Lauderdale, Florida.
About National Pediatric Cancer Foundation
The National Pediatric Cancer Foundation is a nonprofit organization dedicated to funding research to eliminate childhood cancer through the Sunshine Project, the Foundation’s collaborative research initiative. By partnering with doctors and researchers from the country’s top institutions, the Sunshine Project is fast-tracking the development of new drugs and therapies that will ultimately lead to the cure of childhood cancers. The NPCF has received a perfect 100% score for financial health and transparency and is recognized as the top-rated cancer charity in the U.S. by Charity Navigator. For more information, visit www.NationalPCF.org or connect via Facebook, Twitter or Instagram. Individuals can also directly donate to the cause through the website.
Please consider making a donation today!
Your donation helps fund better treatments specifically for kids battling cancer.